| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514421000 | Chalcogen bonded directly to ring carbon of the five-membered hetero ring (e.g., adrenochrome, etc.) | 12 |
| 20080280968 | METHODS OF USING [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF FOR TREATING INFECTIOUS DISEASES - Disclosed are methods of treating infectious diseases comprising administering to the animal, a therapeutically effective amount of a heterocyclic compound. The animal is a mammal, preferably a human or a rodent. | 11-13-2008 |
| 20090069401 | MARINE ACTINOMYCETE TAXON FOR DRUG AND FERMENTATION PRODUCT DISCOVERY - The invention is the discovery of an actinomycete genus, given the name | 03-12-2009 |
| 20090197937 | MARINE ACTINOMYCETE TAXON FOR DRUG AND FERMENTATION PRODUCT DISCOVERY - The invention is the discovery of an actinomycete genus, given the name | 08-06-2009 |
| 20090298906 | PROTEASOME INHIBITORS - Disclosed herein are compounds of Formula (I) that include a sulfonate ester, ester or ether group. Compounds of Formula (I) can be included in pharmaceutical compositions, and can be used to treating and/or ameliorating a disease or condition, such as cancer, a microbial disease and/or inflammation. | 12-03-2009 |
| 20090318529 | SALINOSPORAMIDES AND METHODS FOR USE THEREOF - The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet | 12-24-2009 |
| 20100144826 | Salinosporamides and Methods for Use Thereof - The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet | 06-10-2010 |
| 20110015248 | SUBSTITUTED HETEROCYCLES - The present invention relates to substituted heterocycles, processes for their preparation, and their use in medicaments, especially for the treatment of inflammatory disease, i.e. asthma, or cancer. | 01-20-2011 |
| 20110172285 | PROTEASOME INHIBITORS - Disclosed herein are compounds of Formula (I) that include a sulfonate ester, ester or ether group. Compounds of Formula (I) can be included in pharmaceutical compositions, and can be used to treating and/or ameliorating a disease or condition, such as cancer, a microbial disease and/or inflammation. | 07-14-2011 |
| 20120041045 | USE OF PHARMACEUTICAL COMPOSITIONS CONTAINING MESEMBRENONE - The use of mesembrenone and medicaments and dietary supplements containing mesembrenone. The applicant has surprisingly found that mesembrenone exhibits potent PDE-4 inhibition properties and, in addition to being useful in treating conditions that respond to treatment with a PDE-4 inhibitor, has dual activity on account of its serotonin-uptake inhibition properties. Mesembrenone is extracted and isolated, for example as a pure compound, from plant material of the plant family Mesembryan-themaceae. Preferably a plant or plants from the genus | 02-16-2012 |
| 20120270919 | PROTEASOME INHIBITORS - Disclosed herein are compounds of Formula (I) that include a sulfonate ester, ester or ether group. Compounds of Formula (I) can be included in pharmaceutical compositions, and can be used to treating and/or ameliorating a disease or condition, such as cancer, a microbial disease and/or inflammation. | 10-25-2012 |
| 20140256782 | Opsin-Binding Ligands, Compositions and Methods of Use - Compounds are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic is visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed. | 09-11-2014 |
| 20160081330 | ECTOPARASITICIDAL FORMULATIONS - The invention provides an ectoparasiticidal formulation which comprises an ectoparasiticidal agent, preferably the pyrethroid tetramethrin, as the pesticidally-active ingredient, together with a crystallization inhibitor selected from the group consisting of alkyl-substituted pyrrolidones, and optionally, one or more organic solvents and/or co-solvents. Preferably, the crystallization inhibitor is N-octyl pyrrolidone, and the organic solvent, if present, preferably comprises diethylene glycol monoethyl ether. The ectoparasiticidal formulation surprisingly yields a significantly enhanced speed of kill. Methods for manufacturing the formulation, as well as methods for treating animals infested with ectoparasites, are also disclosed. | 03-24-2016 |
